文献速递甲状腺与浅表US

ACR TIRADS与AI TIRADS对未推荐活检恶性甲状腺结节的比较分析

Analysis and Comparison of the Malignant Thyroid Nodules Not Recommended for Biopsy in ACR TIRADS and AI TIRADS With a Large Sample of Surgical Series.
PubMed 文献 · J Ultrasound Med · 2022-11-17

本研究回顾性分析3499个有手术病理的甲状腺结节,用ACR TIRADS和AI TIRADS分类。1608个恶性结节中,ACR TIRADS有974个不推荐活检,AI TIRADS有967个。AI TIRADS的不必要FNA率和漏诊癌率更低(41.0% vs 47.8%和22.8% vs 27.5%,P<.05),特异性与AUC更高,但敏感度更低(65.0% vs 57.9%、0.895 vs 0.881、96.1% vs 97.8%,均P<.05)。

要点

  • AI TIRADS较ACR TIRADS漏诊癌率更低(22.8% vs 27.5%),不必要FNA率也更低。
  • 两系统未活检恶性结节中过半可通过超声随访监测(ACR 60.0% vs AI 62.8%)。
  • 建议无需进一步评估的恶性结节中,>90%直径<10 mm。

核心结论

  • 在随访阈值下,ACR TIRADS和AI TIRADS未活检的恶性结节中超过半数可通过超声随访监测,且AI TIRADS漏诊癌率更低。
  • AI TIRADS较ACR TIRADS不必要FNA率和漏诊癌率更低,但敏感度更低、特异性和AUC更高。
  • 建议无需进一步评估的恶性结节中,ACR TIRADS有97.4%(380/390)、AI TIRADS有93.3%(336/360)直径<10 mm。

研究设计与样本

  • 回顾性研究,纳入3499个有手术组织病理学和超声特征的甲状腺结节。
  • 使用ACR TIRADS和AI TIRADS对结节进行分类,并按活检和随访建议分为FNA、超声随访和无需进一步评估三组。

诊断标准与关键数值

  • 共1608个恶性结节,ACR TIRADS不推荐活检974个,AI TIRADS不推荐活检967个。
  • 不推荐活检的恶性结节中,ACR TIRADS有60.0%(584/974)、AI TIRADS有62.8%(607/967)可进行超声随访。
  • 无需进一步评估的恶性结节中,ACR TIRADS有97.4%(380/390)、AI TIRADS有93.3%(336/360)直径<10 mm。
  • AI TIRADS vs ACR TIRADS:不必要FNA率41.0% vs 47.8%,漏诊癌率22.8% vs 27.5%(P<.05)。
  • AI TIRADS vs ACR TIRADS:特异度65.0% vs 57.9%,AUC 0.895 vs 0.881,敏感度96.1% vs 97.8%(均P<.05)。

临床应用与阅片要点

  • 对于未达到活检阈值的结节,应结合随访阈值判断是否超声监测,避免过度活检。
  • AI TIRADS可降低不必要FNA率和漏诊癌率,但敏感度略低,阅片时需注意假阴性风险。

局限性

  • 回顾性研究设计。
  • 单中心研究。
  • 仅纳入有手术病理的结节,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine if the artificial intelligence-based Thyroid Imaging, Reporting and Data System (AI TIRADS) would perform better than the American College of Radiology (ACR) TIRADS in monitoring malignant thyroid nodules not recommended for biopsy using follow-up thresholds.

METHODS: A total of 3499 thyroid nodules with surgical histopathology and ultrasound features were retrospectively reviewed and categorized using ACR TIRADS and AI TIRADS. The recommendations for biopsy and follow-up divided nodules into three groups 1) fine needle aspiration (FNA), 2) follow-up ultrasound, and 3) no further evaluation.

RESULTS: Of the total 1608 malignant nodules in this study, 974 malignant nodules would not be biopsied in ACR TIRADS compared with 967 in AI TIRADS. While 60.0% (584/974) of these non-biopsied malignancies could be followed-up by ultrasound in ACR TIRADS and 62.8% (607/967) in AI TIRADS. For the malignancies of no further evaluation, 97.4% (380/390) were sized <10 mm in ACR TIRADS and 93.3% (336/360) in AI TIRADS. Compared with ACR TIRADS, AI TIRADS had lower unnecessary FNA rate and missing cancer rate (41.0% vs 47.8% and 22.8% vs 27.5%, P < .05, respectively) while having higher specificity and AUC as well as lower sensitivity (65.0% vs 57.9%, 0.895 vs 0.881, and 96.1% vs 97.8%, all P < .05).

CONCLUSIONS: Using the follow-up thresholds, more than half of the malignancies not being biopsied were monitored by ultrasound in both ACR TIRADS and AI TIRADS, and AI TIRADS had lower missing cancer rate. More than 90% of malignancies recommended for no further evaluation were <10 mm in diameter.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Cui, Fu, Si, et al. Analysis and Comparison of the Malignant Thyroid Nodules Not Recommended for Biopsy in ACR TIRADS and AI TIRADS With a Large Sample of Surgical Series. J Ultrasound Med. 2022. PMID: 36394431. doi:10.1002/jum.16132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。